Skip to main content
SpringerLink
Log in

Preventive and Therapeutic Implications of Positive CDH1 Testing in Diffuse Gastric Cancer

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS. Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery. 2011;149:347–55.

    Article  PubMed  Google Scholar 

  2. Chen Y, Kingham K, Ford JM, et al. A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Ann Surg Oncol. 2011. doi:10.1245/s10434-011-1648-9.

  3. Ziogas D, Roukos DH. CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol. 2009;16(10):2678–81.

    Article  PubMed  Google Scholar 

  4. Roukos DH. Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol. 2011;18(1):12–15.

    Article  PubMed  Google Scholar 

  5. Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Per Med. 2010;7(4):347–50.

    Article  CAS  Google Scholar 

  6. Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 2011;11(2):81–92.

    Article  PubMed  CAS  Google Scholar 

  7. Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices. 2010;7(6):723–6.

    Article  PubMed  CAS  Google Scholar 

  8. Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics. 2010;11(8):1039–43.

    Article  PubMed  CAS  Google Scholar 

  9. Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med. 2010;4(4):583–6.

    Article  PubMed  Google Scholar 

  10. Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn. 2010;10(5):541–5.

    Article  PubMed  CAS  Google Scholar 

  11. Roukos DH. Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices. 2011;8(4):409–13.

    Article  PubMed  Google Scholar 

  12. Roukos DH. Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices. 2011;8(2):123–6.

    Article  PubMed  CAS  Google Scholar 

  13. Roukos DH. Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics. 2011;12(5):695–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chirurgische Klinik, St. Elisabethenkrankenhaus, Frankfurt, Germany

    Christof Hottenrott MD

Authors
  1. Christof Hottenrott MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christof Hottenrott MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hottenrott, C. Preventive and Therapeutic Implications of Positive CDH1 Testing in Diffuse Gastric Cancer. Ann Surg Oncol 18 (Suppl 3), 192–193 (2011). https://doi.org/10.1245/s10434-011-1937-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-011-1937-3

Keywords

Search

Navigation